Advertisement
Advertisement
BOLT
Bolt Biotherapeutics, Inc. Common Stock
3.99
USDSponsored
-0.06
-1.48%
Aug 10, 16:00 UTC -4
Closed
After-Market
4.05
+0.06
+1.58%
BOLT Earnings Reports
Positive Surprise Ratio
BOLT beat 16 of 22 last estimates.
73%
Next Report
In 2 Days
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$510.00K
/-$3.45
Implied change from Q1 26 (Revenue/ EPS)
+1861.54%
/-19.77%
Implied change from Q2 25 (Revenue/ EPS)
-71.73%
/-22.65%
Bolt Biotherapeutics, Inc. Common Stock earnings per share and revenue
On May 12, 2026, BOLT reported earnings of -4.30 USD per share (EPS) for Q1 26, missing the estimate of -2.90 USD, resulting in a -48.26% surprise. Revenue reached 26.00 thousand, compared to an expected 1.53 million, with a -98.30% difference. The market reacted with a +1.05% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -3.45 USD, with revenue projected to reach 510.00 thousand USD, implying an decrease of -19.77% EPS, and increase of 1861.54% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bionano Genomics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.64
Surprise
+8.40%
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
What were Bolt Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Bolt Biotherapeutics, Inc. Common Stock reported EPS of -$4.30, missing estimates by -48.26%, and revenue of $26.00K, -98.3% below expectations.
How did the market react to Bolt Biotherapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 1.05%, changed from $4.78 before the earnings release to $4.83 the day after.
When is Bolt Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Bolt Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 4
analysts, Bolt Biotherapeutics, Inc. Common Stock is expected to report EPS of -$3.45 and revenue of $510.00K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement